Introduction
Living with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) can affect nearly every part of daily life. Many patients experience progressive nerve damage that may lead to numbness, tingling, weakness, pain, mobility problems, and reduced quality of life over time. Managing a rare condition like hATTR amyloidosis often requires ongoing specialty care, long-term monitoring, and access to advanced medications.
Amvuttra is an innovative RNA interference therapy developed to help treat the nerve-related complications of hATTR amyloidosis. The medication works by targeting transthyretin (TTR) protein production in the liver, helping reduce the buildup of abnormal proteins that contribute to nerve and tissue damage throughout the body.
Unlike some traditional therapies, Amvuttra uses small interfering RNA (siRNA) technology to “silence” the genetic instructions that produce transthyretin protein. By lowering TTR levels, the medication may help slow disease progression and improve symptoms for some patients living with this rare inherited condition.